Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;50(12):3952-9.
doi: 10.1128/JCM.01130-12. Epub 2012 Oct 3.

In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study

Affiliations

In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study

He Wang et al. J Clin Microbiol. 2012 Dec.

Abstract

We conducted active, laboratory-based surveillance for isolates from patients with invasive infections across China from August 2009 to July 2010. DNA sequencing methods were used to define species, and susceptibility to fluconazole and voriconazole was determined by the Clinical and Laboratory Standards Institute M44-A2 disk diffusion method but using up-to-date clinical breakpoints or epidemiological cutoff values. Candida spp. made up 90.5% of the 814 yeast strains isolated, followed by Cryptococcus neoformans (7.7%) and other non-Candida yeast strains (1.7%). Bloodstream isolates made up 42.9% of the strains, isolates from ascitic fluid made up 22.1%, but pus/tissue specimens yielded yeast strains in <5% of the cases. Among the Candida isolates, Candida albicans was the most common species from specimens other than blood (50.1%) but made up only 23% of the bloodstream isolates (P < 0.001). C. parapsilosis complex species were the most common Candida isolates from blood (33.2%). Uncommon bloodstream yeast strains included Trichosporon spp., C. pelliculosa, and the novel species C. quercitrusa, reported for the first time as a cause of candidemia. Most (>94%) of the isolates of C. albicans, C. tropicalis, and the C. parapsilosis complex were susceptible to fluconazole and voriconazole, as were all of the Trichosporon strains; however, 12.2% of the C. glabrata sensu stricto isolates were fluconazole resistant and 17.8% had non-wild-type susceptibility to voriconazole. Seven C. tropicalis strains were cross-resistant to fluconazole and voriconazole; six were from patients in the same institution. Resistance to fluconazole and voriconazole was seen in 31.9% and 13.3% of the uncommon Candida and non-Candida yeast strains, respectively. Causative species and azole susceptibility varied with the geographic region. This study provided clinically useful data on yeast strains and their antifungal susceptibilities in China.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Distribution of the 12 surveillance sites that participated in CHIF-NET 2010 in China. Hospital codes: BD, Peking University First Hospital; GZ, The First Affiliated Hospital of Sun Yat-Sen University; H1, The First Affiliated Hospital of Harbin Medical University; H4, the Fourth Affiliated Hospital of Harbin Medical University; HX, West China Hospital; LR, The People's Hospital of Liaoning Province; NJ, Nanjing General Hospital of PLA; PU, Peking Union Medical College Hospital; RJ, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University; TJ, Tianjin Medical University General Hospital; Tongji Hospital; TZ, Tianjin Medical University General Hospital; Z1, The First Hospital of China Medical University.
Fig 2
Fig 2
Geographic variations of C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, Cryptococcus neoformans, and other yeast species at 12 surveillance sites.

References

    1. Arendrup MC, et al. 2008. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 14:487–494 - PubMed
    1. Arendrup MC, et al. 2011. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J. Clin. Microbiol. 49:3300–3308 - PMC - PubMed
    1. Arnold HM, et al. 2010. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30:361–368 - PubMed
    1. Borman AM, et al. 2008. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J. Clin. Microbiol. 46:933–938 - PMC - PubMed
    1. Chen S, et al. 2006. Active surveillance for candidemia, Australia. Emerg. Infect. Dis. 12:1508–1516 - PMC - PubMed

Publication types